MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Jain, Ankit P.
Patil, Arun H.
Keshava Prasad, T. S.
Mathur, Premendu Prakash
Text and Data Mining valid from 2019-12-01
9 July 2019
11 November 2019
11 December 2019
The authors declare no competing interests.